NCT02528903

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of MHAB5553A in Healthy Volunteers

A Phase 1, Randomized, Double-blind, Placebo-controlled, Single-ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of MHAB5553A in Healthy Volunteers

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 26 (actual)
• Sponsor: Genentech, Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

This is a Phase 1, randomized, double-blind, placebo-controlled, single-ascending dose study in healthy volunteers to investigate the safety, tolerability, and pharmacokinetics (PK) of MHAB5553A.

Conditions

• Healthy Volunteer

Interventions

Type	Name	Description
DRUG	MHAB5553A	Single intravenous administration, at various doses, depending on the cohort
DRUG	Matching placebo	Single intravenous dose

Timeline

• Start date: 2015-08-18
• Primary completion: 2016-01-26
• Completion: 2016-01-26
• First posted: 2015-08-19
• Last updated: 2019-10-01

Locations

1 site across 1 country: Canada